Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
7
×
life sciences
national blog main
san francisco blog main
7
×
boston blog main
boston top stories
national top stories
san francisco top stories
deals
gene editing
new york blog main
new york top stories
san diego blog main
san diego top stories
boulder/denver blog main
boulder/denver top stories
celgene
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alzheimer's disease
biogen
boston
cancer
crispr
drug prices
editas medicine
enzyme
gene therapy
hemophilia
What
gene
7
×
bio
editing
medicine
roundup
therapy
drug
editas
therapeutics
treatment
abbvie
advanced
alliance
alnylam’s
alzheimer’s
approval
beam
becker
benefit
bff
billions
biotech
cas
companies
conference
crispr
crude
cutting
deals
despite
devoted
different
disease
dollars
easl
eaton
edge
editor
effects
encoded
Language
unset
Current search:
biotech
×
gene
×
" san francisco blog main "
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
In Landmark Gene-Editing Study, Sangamo Reports Little Benefit
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M